Another unreasonable suppression! The U.S. House of Representatives has passed the Biosecurity Act, and wuxi apptec and wuxi bio have quickly responded.

①The U.S. House of Representatives passed the draft of the Biosecurity Act (H.R.8333) with 306 votes in favor and 81 votes against. ②Wuxi Apptec, Wuxi Bio, and other companies strongly opposed it. ③This bill still needs to be voted on by the Senate and the versions passed by both houses need to be reconciled before it can be submitted to the U.S. President for signing into law.

cls.cn21:06 ET

Akeso defeats the "Medicine King".

The success of innovative drugs is not only a technological success, but also a financial success.

wallstreetcnSep 9 04:10 ET

BeiGene Stock Rises on FDA Fast Track Tag for Investigational Cancer Therapy

Seeking AlphaAug 26 07:07 ET

Yasheng Pharmaceuticals has also landed | JIANZHI Research

One step closer to regular profitability.

wallstreetcnAug 23 01:14 ET

WuXi AppTec's joint venture, Pharmapace, has gained benefits from the ADC industry. | Jianzhi Research

Net profit increased by 175% year-on-year, exceeding expectations, but the market's extreme pessimism has not yet been eliminated.

wallstreetcnAug 21 02:17 ET

The growth rate of all channels of dressing in the second half of the year may be slightly lower than that in the first half. Juzi Biotech stated that it will continue to expand the number of terminal stores. Earnings conference coverage.

At the earnings conference, Juzi Biotech predicted that products such as wrinkle fillers may obtain registration certificates in the first quarter of next year. The company's secretary, Yan Yubo, stated that due to the impact of online growth, the overall growth rate of all channels of dressings may be slightly lower than the first half of the year. The company's CFO, Zhang Huijuan, expects that the growth rate in the CS/KA channel will further slow down in the second half of the year.

cls.cnAug 20 02:04 ET